Le Plessis Bouchard, France

Pierre Sokoloff


Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 1995-2011

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Pierre Sokoloff: Innovator in Neuropsychological Therapeutics

Introduction

Pierre Sokoloff is a notable inventor based in Le Plessis Bouchard, France. He has made significant contributions to the field of neuropsychological therapeutics, holding a total of 7 patents. His work primarily focuses on the development of novel pharmaceutical compounds that target specific receptors in the brain.

Latest Patents

Among his latest patents, one notable invention is the development of 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands. This invention relates to pharmaceutical compositions containing these derivatives and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor. This work aims to provide new treatment options for various neuropsychological disorders. Another significant patent involves 2-naphthamide derivatives, which are presented in the form of bases or salts. These derivatives correspond to a specific general formula and represent a promising avenue for therapeutic applications.

Career Highlights

Throughout his career, Pierre Sokoloff has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Adir et Compagnie. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Pierre has collaborated with notable colleagues, including Jean-Charles Schwartz and Fabrice Garrido. These partnerships have enriched his research and fostered innovation in the field.

Conclusion

Pierre Sokoloff's contributions to neuropsychological therapeutics through his patents and collaborations highlight his role as a significant inventor in the pharmaceutical industry. His work continues to pave the way for advancements in treatment options for neuropsychological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…